Pediatric migraine focus Theranica’s Nerivio REN wearable targets pediatric and adolescent migraine management, presenting a direct sales angle to pediatric neurology clinics, universities, and pediatric hospitals seeking non-drug, non-invasive solutions with FDA clearance for ages 8 and up.

Non-drug market leadership The device offers a drug-free alternative with a favorable safety profile, which can be positioned to payer networks and hospital committees as a preferred option for patients with contraindications or intolerance to migraine medications.

Regulatory clearance leverage With FDA clearance and CE marking, there is a strong basis for rapid hospital adoption and cross-border expansion discussions, including expansion into EU markets and potential private payer partnerships.

Strong adoption signals Reported usage of over 650,000 migraine treatments and ongoing recognition from awards demonstrate market validation, which can support sales outreach to clinicians, case managers, and patient advocacy groups.

Data and AI readiness The tech stack includes cloud analytics and AI capabilities (BigQuery, Vertex AI), enabling opportunities to offer outcome tracking, remote monitoring, and value-based care data to health systems and research collaborations.